Ara-C scheduling: Theoretical and experimental considerations

Joe Gray, M. G. Pallavicini

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In this paper, we discuss the cytokinetic basis for optimization of cancer therapy in humans. Specifically, we define a quantitative procedure for determination of the therapeutic acceptability of therapy schedule, discuss studies of the therapeutic gain that might result from treatment of acute lymphoid leukemia (ALL) with cytosine arabinoside (Ara-C), and indicate the kinds of cytokinetic information necessary for therapy scheduling. These studies suggest 1) that substantial therapeutic improvements may result from optimal therapy scheduling, 2) that therapy schedules selected at random are not likely to be beneficial, and 3) that consideration of the cytokinetic properties of the dose limiting normal tissues is critical during therapy design. We also discuss experimental studies of the response to Ara-C of the murine KHT sarcoma. These studies illustrate that substantial cytokinetic changes occur during therapy (e.g., a substantial increase in cell cycle traverse rate and almost complete recrutitiment) and show the importance of obtaining mid-treatment cytokinetic information about normal and malignant tissues.

Original languageEnglish (US)
Pages (from-to)93-108
Number of pages16
JournalMedical and Pediatric Oncology
Volume10
Issue numberSuppl. 1
StatePublished - 1982
Externally publishedYes

Fingerprint

Cytarabine
Therapeutics
Appointments and Schedules
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Sarcoma
Cell Cycle

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

Ara-C scheduling : Theoretical and experimental considerations. / Gray, Joe; Pallavicini, M. G.

In: Medical and Pediatric Oncology, Vol. 10, No. Suppl. 1, 1982, p. 93-108.

Research output: Contribution to journalArticle

Gray, Joe ; Pallavicini, M. G. / Ara-C scheduling : Theoretical and experimental considerations. In: Medical and Pediatric Oncology. 1982 ; Vol. 10, No. Suppl. 1. pp. 93-108.
@article{27e6ddd33f0444ed8e759ea6a5ddcee8,
title = "Ara-C scheduling: Theoretical and experimental considerations",
abstract = "In this paper, we discuss the cytokinetic basis for optimization of cancer therapy in humans. Specifically, we define a quantitative procedure for determination of the therapeutic acceptability of therapy schedule, discuss studies of the therapeutic gain that might result from treatment of acute lymphoid leukemia (ALL) with cytosine arabinoside (Ara-C), and indicate the kinds of cytokinetic information necessary for therapy scheduling. These studies suggest 1) that substantial therapeutic improvements may result from optimal therapy scheduling, 2) that therapy schedules selected at random are not likely to be beneficial, and 3) that consideration of the cytokinetic properties of the dose limiting normal tissues is critical during therapy design. We also discuss experimental studies of the response to Ara-C of the murine KHT sarcoma. These studies illustrate that substantial cytokinetic changes occur during therapy (e.g., a substantial increase in cell cycle traverse rate and almost complete recrutitiment) and show the importance of obtaining mid-treatment cytokinetic information about normal and malignant tissues.",
author = "Joe Gray and Pallavicini, {M. G.}",
year = "1982",
language = "English (US)",
volume = "10",
pages = "93--108",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "Suppl. 1",

}

TY - JOUR

T1 - Ara-C scheduling

T2 - Theoretical and experimental considerations

AU - Gray, Joe

AU - Pallavicini, M. G.

PY - 1982

Y1 - 1982

N2 - In this paper, we discuss the cytokinetic basis for optimization of cancer therapy in humans. Specifically, we define a quantitative procedure for determination of the therapeutic acceptability of therapy schedule, discuss studies of the therapeutic gain that might result from treatment of acute lymphoid leukemia (ALL) with cytosine arabinoside (Ara-C), and indicate the kinds of cytokinetic information necessary for therapy scheduling. These studies suggest 1) that substantial therapeutic improvements may result from optimal therapy scheduling, 2) that therapy schedules selected at random are not likely to be beneficial, and 3) that consideration of the cytokinetic properties of the dose limiting normal tissues is critical during therapy design. We also discuss experimental studies of the response to Ara-C of the murine KHT sarcoma. These studies illustrate that substantial cytokinetic changes occur during therapy (e.g., a substantial increase in cell cycle traverse rate and almost complete recrutitiment) and show the importance of obtaining mid-treatment cytokinetic information about normal and malignant tissues.

AB - In this paper, we discuss the cytokinetic basis for optimization of cancer therapy in humans. Specifically, we define a quantitative procedure for determination of the therapeutic acceptability of therapy schedule, discuss studies of the therapeutic gain that might result from treatment of acute lymphoid leukemia (ALL) with cytosine arabinoside (Ara-C), and indicate the kinds of cytokinetic information necessary for therapy scheduling. These studies suggest 1) that substantial therapeutic improvements may result from optimal therapy scheduling, 2) that therapy schedules selected at random are not likely to be beneficial, and 3) that consideration of the cytokinetic properties of the dose limiting normal tissues is critical during therapy design. We also discuss experimental studies of the response to Ara-C of the murine KHT sarcoma. These studies illustrate that substantial cytokinetic changes occur during therapy (e.g., a substantial increase in cell cycle traverse rate and almost complete recrutitiment) and show the importance of obtaining mid-treatment cytokinetic information about normal and malignant tissues.

UR - http://www.scopus.com/inward/record.url?scp=0020460692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020460692&partnerID=8YFLogxK

M3 - Article

C2 - 6962324

AN - SCOPUS:0020460692

VL - 10

SP - 93

EP - 108

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - Suppl. 1

ER -